<DOC>
	<DOCNO>NCT00761137</DOCNO>
	<brief_summary>The primary goal study evaluate safety potential efficacy intra-oral dissolvable NH004 film improve short-term symptom sialorrhea ( drool ) Parkinson 's disease ( PD ) patient .</brief_summary>
	<brief_title>Safety Efficacy Study NH004 Films Relief Sialorrhea Symptoms Parkinson 's Disease Patients</brief_title>
	<detailed_description>NH004 contain anticholinergic agent tropicamide deliver convenient product form ( intra-oral dissolvable thin film ) design management sialorrhea . This study double blind , placebo-controlled , crossover study safety potential efficacy three dos NH004 film short-term relief symptom sialorrhea Parkinson 's disease patient . A total 36 Parkinson 's disease patient enrol study two Phases . Phase A include 12 patient Phase B 24 patient . There interim analysis conclusion Phase A . In phase patient randomize one four group . Each group distinctive sequence receive intra-oral dissolvable film 0.3 mg , 1 mg , 3 mg NH004 , placebo four visit .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Sialorrhea</mesh_term>
	<mesh_term>Tropicamide</mesh_term>
	<criteria>1 . Patients idiopathic Parkinson 's disease , accord United Kingdom Brain Bank criterion . 2 . Patients complain drooling , score least 3 FLENI Sialorrhea scale . 3 . Patient 50 80 year age , inclusive . 4 . Male nonpregnant female . Females childbearing potential require undergone pregnancy test negative result prior entry study agree use contraceptive measure duration study . 5 . Patients must use medication dose PD last month . No change medication PD expect study . 6 . Patients reasonable expect `` onstate '' duration test procedure . 7 . Patients stable response levodopa PD . 1 . Pregnant woman woman may become pregnant . 2 . Patients diagnosis depression , schizophrenia obvious symptom disease . 3 . Patients MiniMental State Examination ( MMSE ) score equal low 26 . 4 . Patients receive follow drug : tricyclic antidepressant , Monoamine Oxidase Inhibitors ( MAOI 's ) , neuroleptic ( antipsychotic ) , anticholinergic . 5 . Patients take drug mention exclusion criterion number 4 within last week . 6 . Patients hypersensitivity atropine anticholinergic drug . 7 . Patients experienced adverse effect result take anticholinergic drug . 8 . Patients take hypnotic sleep inducing drug . 9 . Patients severe urinary gastrointestinal symptom . 10 . Patients significant dental/oral pathology . 11 . Patients severe dysautonomia .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>sialorrhea</keyword>
	<keyword>drool</keyword>
	<keyword>excessive salivation</keyword>
	<keyword>parkinson 's disease</keyword>
</DOC>